

Elena Toschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7046877/publications.pdf>

Version: 2024-02-01

27
papers

1,362
citations

394286

19
h-index

552653

26
g-index

27
all docs

27
docs citations

27
times ranked

1893
citing authors

#	ARTICLE	IF	CITATIONS
1	Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic. <i>Trials</i> , 2022, 23, .	0.7	0
2	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	2.8	50
3	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4320.	1.8	43
4	Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. <i>Oncology Letters</i> , 2017, 13, 2903-2908.	0.8	8
5	Antitumor Effects of Epidrug/IFN γ Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells. <i>Cancer Immunology Research</i> , 2017, 5, 604-616.	1.6	27
6	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. <i>Scientific Reports</i> , 2017, 7, 1093.	1.6	130
7	IFN γ potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 26361-26373.	0.8	25
8	HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. <i>Current Drug Targets</i> , 2015, 17, 33-45.	1.0	19
9	Apicidin and Docetaxel Combination Treatment Drives CTCFL Expression and HMGB1 Release Acting as Potential Antitumor Immune Response Inducers in Metastatic Breast Cancer Cells. <i>Neoplasia</i> , 2012, 14, 855-IN19.	2.3	31
10	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56
11	Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>International Journal of Vascular Medicine</i> , 2011, 2011, 1-8.	0.4	12
12	The Activity of Matrix Metalloproteinase-9 is Part of the Mechanism of Cell-to-Cell HIV-1 Endocytosis in Dendritic Cells. <i>Current Drug Discovery Technologies</i> , 2011, 8, 112-118.	0.6	2
13	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors <i>via</i> a proteasome-independent block of angiogenesis and matrix metalloproteinases. <i>International Journal of Cancer</i> , 2011, 128, 82-93.	2.3	40
14	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. <i>Aids</i> , 2009, 23, 534-538.	1.0	31
15	Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9. <i>Journal of Virology</i> , 2007, 81, 9078-9087.	1.5	20
16	Control of Human Herpes Virus Type 8-Associated Diseases by NK Cells. <i>Annals of the New York Academy of Sciences</i> , 2007, 1096, 37-43.	1.8	8
17	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. <i>Molecular Biology of the Cell</i> , 2006, 17, 1985-1994.	0.9	66
18	The use of HAART for biological tumour therapy. <i>Journal of HIV Therapy</i> , 2006, 11, 53-6.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Antitumour effects of antiretroviral therapy. <i>Nature Reviews Cancer</i> , 2004, 4, 861-875.	12.8	95
20	HIV protease inhibitors as new treatment options for Kaposi's sarcoma. <i>Drug Resistance Updates</i> , 2003, 6, 173-181.	6.5	13
21	Treatment of Kaposi's sarcoma—an update. <i>Anti-Cancer Drugs</i> , 2002, 13, 977-987.	0.7	24
22	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. <i>Nature Medicine</i> , 2002, 8, 225-232.	15.2	299
23	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. <i>Molecular Biology of the Cell</i> , 2001, 12, 2934-2946.	0.9	110
24	Wild-Type p53 Gene Transfer Inhibits Invasion and Reduces Matrix Metalloproteinase-2 Levels in p53-Mutated Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1188-1194.	0.3	40
25	Shear Stress Downregulation of Platelet-Derived Growth Factor Receptor- β 2 and Matrix Metalloproteinase-2 Is Associated With Inhibition of Smooth Muscle Cell Invasion and Migration. <i>Circulation</i> , 2000, 102, 225-230.	1.6	89
26	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394.	1.2	43
27	Mechanism of Paclitaxel Activity in Kaposi's Sarcoma. <i>Journal of Immunology</i> , 2000, 165, 509-517.	0.4	75